Dara RVD: Four-Drug Strategy Strengthening Multiple Myeloma Care

Adding the antibody daratumumab to the longstanding three-drug backbone of bortezomib, lenalidomide, and dexamethasone produces a four-drug combination (commonly abbreviated D-VRd or Dara-VRd) that has become the recommended first-line treatment for most people diagnosed with multiple myeloma. In the pivotal PERSEUS trial, patients given the four-drug regimen had roughly 84% progression-free survival at four years compared with about 68% for those on the three-drug version alone, cutting the risk of disease progression or death by more than half.¹ That improvement, confirmed across both transplant-eligible and transplant-ineligible populations, reshaped treatment guidelines in 2025 and made D-VRd the new standard of care.

What Each Drug Brings to the Combination

The three-drug backbone, VRd, has been a workhorse in myeloma treatment for over a decade. Bortezomib is a proteasome inhibitor that blocks a cellular recycling system myeloma cells rely on to survive. Lenalidomide is an immunomodulatory drug that both kills myeloma cells directly and helps the immune system recognize them. Dexamethasone is a steroid that amplifies the cancer-killing effects of the other two while reducing inflammation. Each drug attacks myeloma through a different pathway, which is why the triplet works better than any one of them alone.

Daratumumab, the fourth drug, is an antibody that latches onto a protein called CD38, which sits on the surface of myeloma cells in unusually high amounts. Once daratumumab binds to CD38, it triggers several immune-system attacks on the cancer cell: it flags the cell for destruction by natural killer cells, recruits macrophages to engulf it, activates the complement system to punch holes in its membrane, and can push the cell into programmed death.² Because its mechanism of action is completely different from the other three drugs, daratumumab stacks additional killing power on top of an already effective backbone without simply amplifying the same pathway.

The Trial Evidence That Changed the Guidelines

The road to D-VRd becoming the standard ran through two major clinical trials, each building confidence in the four-drug approach.

GRIFFIN (Phase 2)

GRIFFIN enrolled transplant-eligible patients who were newly diagnosed with myeloma. At its initial analysis, the rate of the deepest type of response (stringent complete response) was already trending in favor of D-VRd: about 42% versus 32% for VRd alone after post-transplant consolidation.³ Responses kept deepening over time: at around 22 months of follow-up, stringent complete response rates rose to roughly 63% for D-VRd versus 45% for VRd. By the final analysis at a median follow-up of almost 50 months, the gap widened further, with about two-thirds of D-VRd patients achieving that deepest response compared with under half of the VRd group, and four-year progression-free survival estimated at about 87% versus 70%.⁴

PERSEUS (Phase 3)

PERSEUS was the larger, confirmatory trial, also in transplant-eligible patients. At a median follow-up of about four years, estimated progression-free survival at 48 months was 84.3% with D-VRd versus 67.7% with VRd. The hazard ratio for disease progression or death was 0.42, meaning D-VRd cut the risk by roughly 58%.¹ The rate of complete response or better was about 88% in the D-VRd group compared with 70% with VRd alone. These results crossed the pre-specified statistical boundary early, which led to the data being released ahead of schedule. Based on these findings, the National Comprehensive Cancer Network (NCCN) updated its 2025 guidelines to list quadruplet therapy with an anti-CD38 antibody plus VRd as the primary option for newly diagnosed myeloma.⁵

Why Deeper Responses Matter

One of the most striking features of D-VRd is how often it drives disease to undetectable levels. Minimal residual disease (MRD) testing uses extremely sensitive technology to hunt for as few as one myeloma cell among 100,000 or even a million normal cells. In PERSEUS, about 75% of patients on D-VRd tested MRD-negative at the standard sensitivity threshold, compared with roughly 48% of VRd patients.¹ MRD-negative rates kept climbing over time and were consistently higher with the four-drug regimen at 12, 24, and 36 months. Even at deeper sensitivity (one in a million), the D-VRd group showed a sustained MRD-negativity rate of about 47% versus 19% for VRd.⁶

Why does this matter for the patient? Sustained MRD negativity was associated with improved progression-free survival, meaning that patients whose disease dropped below detection and stayed there tended to go longer before the cancer came back. MRD testing is increasingly used alongside traditional response measures to gauge how well treatment is working and whether adjustments are needed.

D-VRd for Patients Who Do Not Get a Transplant

A significant portion of myeloma patients are not candidates for stem cell transplant, whether because of age, other health conditions, or personal preference. The CEPHEUS trial addressed this group specifically, enrolling patients who were either transplant-ineligible or had chosen to defer transplant. Patients received eight cycles of D-VRd or VRd followed by ongoing maintenance.

At a median follow-up of nearly five years, the MRD-negativity rate was about 61% with D-VRd versus 39% with VRd. Complete response rates were roughly 81% versus 62%, and the risk of disease progression or death was 43% lower with the four-drug combination.⁷ These benefits held regardless of whether patients had high-risk or standard-risk genetic features in their myeloma.⁸ That last point is worth emphasizing: high-risk myeloma, defined by certain chromosomal abnormalities, has historically been much harder to treat, so seeing consistent benefit in this subgroup is encouraging.

Does Daratumumab Complicate Stem Cell Collection?

A practical worry that surfaced early in the development of D-VRd was whether daratumumab might interfere with the collection of stem cells for transplant. Lenalidomide was already known to modestly reduce stem cell yields, and there was concern that adding daratumumab could make the problem worse. Data from the GRIFFIN and MASTER trials put much of this concern to rest.

Among D-VRd recipients, only about 2% failed to collect enough stem cells on the first mobilization attempt, and nearly all succeeded on a second try. The median stem cell yield was slightly lower after D-VRd induction compared with VRd alone (about 8.3 versus 9.4 million CD34+ cells per kilogram), but the yields remained well above the minimum needed for transplant. Time to neutrophil recovery after transplant was the same across all groups at a median of 12 days.⁹ In practice, transplant centers have become comfortable managing D-VRd patients through the collection process with standard protocols.

Infection Risk With the Four-Drug Regimen

Every additional drug added to a cancer regimen has the potential to increase side effects, and with D-VRd the most clinically relevant added risk is infection. A systematic review and meta-analysis pooling data from nine randomized trials found that daratumumab-containing regimens were associated with a roughly 29% higher rate of severe (grade 3 or above) infections compared with the same regimens without daratumumab. The risk of pneumonia specifically was about 60% higher.¹⁰ This increased infection risk was seen in both transplant-eligible and transplant-ineligible patients, though it was somewhat more pronounced in the transplant-ineligible group.

The risk is real but manageable. Most treatment protocols now build in prophylaxis against herpes zoster (with antiviral medication) and pneumocystis pneumonia (with a preventive antibiotic). Some centers also use intravenous immunoglobulin supplementation for patients whose antibody levels drop significantly during treatment. Knowing that this infection risk exists allows oncology teams to monitor patients closely and intervene early.

After Transplant, the Role of Maintenance

For patients who undergo stem cell transplant, the standard practice has been long-term maintenance with lenalidomide alone to keep the disease suppressed. Two trials have now explored whether adding daratumumab to maintenance further improves outcomes.

The AURIGA trial studied patients who were still MRD-positive after transplant and randomized them to maintenance with daratumumab plus lenalidomide (D-R) or lenalidomide alone. By 12 months, about half of D-R patients had converted to MRD-negative status compared with about 19% on lenalidomide alone. At a median follow-up of roughly 32 months, progression-free survival favored D-R, with estimated 30-month rates of about 83% versus 66%.¹¹ Similarly, the CASSIOPEIA trial tested daratumumab as maintenance versus observation alone (after a daratumumab-containing induction) and found a significant progression-free survival benefit with continued daratumumab, with a hazard ratio of 0.53.¹² These findings suggest daratumumab has a role beyond induction, helping deepen and sustain responses during the maintenance phase.

Subcutaneous Injection Changed the Patient Experience

Daratumumab was originally given intravenously, which meant lengthy infusions, sometimes seven hours or more for the first dose, along with a notable rate of infusion-related reactions (chills, breathing difficulties, nausea). A subcutaneous formulation, co-formulated with an enzyme that helps the drug absorb under the skin, was tested in the phase 3 COLUMBA trial. The subcutaneous version was non-inferior to the IV version in terms of response rates and drug levels, with a significantly lower rate of administration-related reactions and a dramatically shorter administration time of roughly three to five minutes.¹³

The subcutaneous formulation has become the standard in most countries. For patients on a regimen like D-VRd, the switch from a multi-hour infusion to a brief injection in the thigh is more than a convenience: it shortens clinic visits substantially, reduces the need for pre-medications to prevent reactions, and frees up infusion chairs for other patients. It also makes the regimen more practical in community oncology settings that may lack dedicated infusion bays.

A Lab Quirk That Can Confuse Response Assessment

Daratumumab itself is an IgG-kappa antibody, which means it can show up on the same laboratory tests used to track the patient’s myeloma protein. Specifically, daratumumab appears as a small band on serum immunofixation electrophoresis and, because many myeloma proteins are also IgG-kappa, the two signals can overlap. This overlap can make it look as though a patient still has residual myeloma protein when in fact the signal is entirely from the daratumumab drug itself.¹⁴

This matters because complete response, by international criteria, requires the myeloma protein to be undetectable on immunofixation. If daratumumab’s signal masquerades as residual disease, patients could be denied a complete response classification they actually deserve. A specialized reflex assay (known as the Hydrashift or DIRA test) was developed to shift daratumumab’s band away from the myeloma protein on the gel, letting the lab distinguish the two.¹⁵ If you are being treated with D-VRd and your lab reports suggest a lingering trace of myeloma protein, it is worth asking your oncologist whether the DIRA assay has been run.

Quality of Life on the Four-Drug Regimen

Adding a fourth drug to an already intensive treatment plan raises a reasonable worry: does it make patients feel worse? Patient-reported outcome data from the GRIFFIN trial suggest the opposite. Patients on D-VRd actually reported greater reductions in pain during post-transplant consolidation and throughout maintenance, with a clinically meaningful advantage of at least 20 points on the pain symptom scale compared with VRd alone. Fatigue symptoms also improved more with D-VRd by six months into maintenance, and a measure of overall health status was higher with D-VRd at 18 months of maintenance. The median time before patients reported a worsening in global health status was about 45 months on D-VRd versus about 14 months on VRd.¹⁶ The likely explanation is straightforward: deeper disease control translates to fewer myeloma symptoms (bone pain, fatigue, recurrent infections), which outweighs the added treatment burden of a fourth drug.

When Myeloma Comes Back After D-VRd

As D-VRd becomes the first-line standard, a question that will become increasingly important is what happens when patients relapse. If the myeloma was treated with daratumumab upfront, can daratumumab work again later? Early evidence suggests the answer depends on timing and context. Myeloma cells can downregulate CD38 expression or develop other resistance mechanisms during daratumumab exposure, but CD38 levels may recover after the drug is stopped and the patient receives intervening therapies.

Small studies have examined re-treatment with daratumumab-based regimens after patients have gone through other therapies, including CAR-T cell treatment. Results have been mixed but not hopeless: some patients achieved renewed complete responses on re-treatment, while others did not respond. A drug-sensitivity testing platform is being explored to predict which patients are likely to benefit from re-treatment, though this work is still in its early stages.¹⁷ The broader point is that using daratumumab early does not necessarily burn a bridge for future treatment, but how best to sequence therapies after upfront D-VRd is an active area of investigation.

Moving From Clinical Trials to Everyday Practice

A persistent question with any regimen that works well in clinical trials is whether those results hold up in the real world, where patients tend to be older, have more health conditions, and receive care in community settings rather than academic centers. Early real-world analyses have begun comparing outcomes for D-VRd versus VRd in community practice. While the follow-up is still shorter than in the pivotal trials, the initial data suggest that the progression-free survival advantage seen in PERSEUS and GRIFFIN does translate outside of trial settings.¹⁸

Part of what makes the translation smoother is the subcutaneous formulation. Community oncology practices that might have struggled to manage lengthy IV daratumumab infusions can administer the injection quickly, making the four-drug regimen logistically feasible outside major medical centers. The routine prophylaxis protocols for infection risk are also well-established enough that community oncologists can follow them without specialized infrastructure. The shift toward real-world adoption is happening rapidly, with D-VRd uptake accelerating since the NCCN guideline update.

Monitoring Symptom Burden in Routine Care

As the four-drug regimen becomes standard, oncology teams are also rethinking how they track patient well-being during treatment. Patient-reported outcome tools, which capture symptoms like pain, fatigue, and emotional distress directly from the patient rather than filtered through a clinician’s assessment, are being deployed in routine myeloma care. Early data suggest that individual patients on D-VRd experience unique trajectories of symptom burden over time, with some feeling substantially better early in treatment while others need more intensive supportive care during specific phases like consolidation.¹⁹ Using these tools in practice allows care teams to adjust supportive medications, modify schedules, or intervene before side effects become severe, rather than relying solely on periodic lab work and clinic exams to gauge how a patient is doing.